Drug Trial Radar · NCT07321574
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Nov 28, 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai AB PharmaTech Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- GCP ClinPlus Co., Ltd.
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, multi-cohort investigation exploring the efficacy and safety of ABP1011T tablets in participants with specific target solid tumors, providing a foundation for subsequent clinical research. Based on safety and efficacy data from the prior Phase I/IIa clinical trial (Protocol Number: ABP1011T-I/II-01), priority enrollment is given to participants with advanced solid tumors including small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma (excluding osteosarcoma). Cohort A (Cohort A1, Cohort A2, Cohort A3) comprises the small cell lung cancer cohort: Participants must have failed at least two prior systemic therapies. Cohort B enrolls participants with other advanced solid tumors (excluding osteosarcoma). ABP1011T tablets are administered as continuous therapy in clinical studies, with a 21-day treatment cycle. Participants take one tablet orally once daily on an empty stomach (with water, avoiding food for at least 1 hour before and after each dose).
Conditions
- SCLC, Extensive Stage
- Advanced Solid Tumors
Interventions
ABP1011TDrug
ABP1011T tablets are administered as continuous therapy in clinical studies, with a 21-day treatment cycle. Participants take one tablet orally once daily on an empty stomach (with water, avoiding food for at least 1 hour before and after each dose).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to approximately 2 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Liaocheng Second People's Hospital
Liaocheng, Shandong, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Neijiang First People's Hospital
Neijiang, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.